Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

93.99 

0.52 0.6%

as of Feb 15 '19

52 Week Range:

75.81 106.74


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

BioMarin Pharmaceutical, Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome. The company's commercial products also comprise Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes pegvaliase, an enzyme substitution therapy for the treatment of phenylketonuria; vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans; valoctocogene roxaparvovec, an AAV5 vector and factor VIII gene therapy drug development candidate for the treatment of severe hemophilia A; BMN 250, an investigational enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B or mucopolysaccharidosis type IIIB; and BMN 290, a selective chromatin modulation therapy for the treatment of Friedreich's ataxia. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration agreements with Sarepta Therapeutics and Genzyme Corporation; and a license agreement with Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Equity (BVPS) 1.93
2.77
3.19
6.48
6.75
8.07
8.90
10.12
14.19
15.32
16.00
growth rate 43.5% 15.2% 103.1% 4.2% 19.6% 10.3% 13.7% 40.2% 8.0% 4.4%
Earnings BIT -15.07
33.42
0.57
-21.49
-43.63
-118.28
-176.50
-144.69
-309.96
-261.47
-123.56
growth rate 100.0% -98.3% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Avg.PE -128.70
59.88
-3,232.60
16.45
-63.90
-41.10
-11.69
-11.69
-11.69
-11.69
-77.42
growth rate 100.0% -100.0% 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROA -2.47
3.58
-0.05
18.88
-4.20
-7.87
-9.16
-5.65
-5.52
-16.26
-2.70
growth rate 100.0% -100.0% 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROE -10.34
13.28
-0.16
39.60
-7.22
-12.78
-14.97
-9.34
-8.75
-24.39
-4.20
growth rate 100.0% -100.0% 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROIC -5.18
4.02
0.67
21.93
-4.48
-8.73
-10.13
-5.00
-5.26
-18.62
-1.03
growth rate 100.0% -83.3% 3,173.1% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Cur. Ratio 10.47
5.67
5.98
6.01
4.99
4.36
6.21
6.05
2.45
3.24
2.70
growth rate -45.9% 5.5% 0.5% -17.0% -12.6% 42.4% -2.6% -59.5% 32.2% -16.7%
Quick Ratio 9.79
4.72
4.79
4.39
3.25
3.28
4.92
4.86
1.73
2.29
2.03
growth rate -51.8% 1.5% -8.4% -26.0% 0.9% 50.0% -1.2% -64.4% 32.4% -11.4%
Leverage 4.34
3.28
2.85
1.76
1.69
1.58
1.68
1.63
1.55
1.45
1.65
growth rate -24.4% -13.1% -38.3% -4.0% -6.5% 6.3% -3.0% -4.9% -6.5% 13.8%
Balance Sheet Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Acct.Receivable 54.30
73.50
86.60
125.95
141.42
148.38
201.15
164.96
215.28
261.37
growth rate 35.4% 17.8% 45.4% 12.3% 4.9% 35.6% -18.0% 30.5% 21.4%
Acct.Payable 94.13
147.07
183.27
139.51
179.29
191.35
166.62
growth rate 56.3% 24.6% -23.9% 28.5% 6.7% -12.9%
Cur.Assets 737.70
467.70
504.30
469.80
743.43
1,137.42
1,397.64
1,089.64
1,421.79
2,207.14
growth rate -36.6% 7.8% -6.8% 58.2% 53.0% 22.9% -22.0% 30.5% 55.2%
Total Assets 906.70
917.20
1,262.60
1,305.71
1,568.35
2,244.06
2,475.38
3,729.37
4,023.69
4,633.13
growth rate 1.2% 37.7% 3.4% 20.1% 43.1% 10.3% 50.7% 7.9% 15.2%
Cash 222.90
167.20
88.10
46.27
180.53
568.78
875.49
397.04
408.33
598.03
growth rate -25.0% -47.3% -47.5% 290.1% 215.1% 53.9% -54.7% 2.8% 46.5%
Inventory 73.20
78.70
109.70
130.12
128.70
162.61
199.45
271.68
355.13
475.78
growth rate 7.5% 39.4% 18.6% -1.1% 26.4% 22.7% 36.2% 30.7% 34.0%
Cur.Liabilities 130.10
78.20
83.80
94.13
170.43
183.27
235.74
445.46
439.31
816.52
growth rate -39.9% 7.2% 12.3% 81.1% 7.5% 28.6% 89.0% -1.4% 85.9%
Liabilities 630.00
595.00
545.40
532.66
552.58
903.02
947.49
1,328.52
1,257.42
1,824.46
growth rate -5.6% -8.3% -2.3% 3.7% 63.4% 4.9% 40.2% -5.4% 45.1%
LT Debt 563.93
497.10
497.10
377.50
348.33
324.86
655.57
642.90
662.29
660.76
813.52
growth rate -11.9% 0.0% -24.1% -7.7% -6.7% 101.8% -1.9% 3.0% -0.2% 23.1%
Equity 187.73
276.70
322.20
717.30
773.05
1,015.76
1,341.04
1,527.89
2,400.85
2,766.28
2,808.66
growth rate 47.4% 16.4% 122.6% 7.8% 31.4% 32.0% 13.9% 57.1% 15.2% 1.5%
Common Shares 96.00
104.00
100.00
126.00
112.00
120.00
138.00
146.00
160.00
166.00
174.00
growth rate 8.3% -3.9% 26.0% -11.1% 7.1% 15.0% 5.8% 9.6% 3.8% 4.8%
Cash Flow Statement Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Capital Expenditures 22.41
56.40
89.80
49.50
73.22
44.57
65.19
117.06
227.65
148.38
199.22
growth rate 151.7% 59.2% -44.9% 47.9% -39.1% 46.3% 79.6% 94.5% -34.8% 34.3%
Cash Dividends 0.00 0.00 0.00 0.00 0.00 0.00
growth rate
Cash From OA -35.03
-9.18
87.70
18.70
18.42
17.61
-70.42
-219.50
-227.84
-8.76
growth rate 0.0% 100.0% -78.7% -1.5% -4.4% -100.0% 0.0% 0.0% 0.0%
FCF per Share -0.59
-0.63
-0.02
-0.24
-0.65
-0.22
-0.64
-1.22
-2.21
-3.01
-1.30
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock 33.59
318.56
42.77
197.37
951.30
787.17
60.86
growth rate 848.3% -86.6% 361.5% 382.0% -17.3% -92.3%
FCF -57.00
-66.00
-2.00
-31.00
-135.00
-27.00
-125.00
-192.00
-449.00
-376.00
-208.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Income Statement Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Sales 121.58
296.50
324.70
376.30
441.36
500.72
548.49
749.28
889.90
1,116.85
1,313.65
growth rate 143.9% 9.5% 15.9% 17.3% 13.5% 9.5% 36.6% 18.8% 25.5% 17.6%
Op.Income 39.80
16.40
0.50
-56.26
-115.57
-177.50
-144.69
-309.96
-261.47
-123.56
growth rate -58.8% -97.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
IBT 33.40
0.60
-21.50
-43.63
-118.28
-176.50
-124.87
-154.72
-831.05
-35.88
growth rate -98.2% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Net Income 30.80
-0.50
205.80
-56.26
-115.57
-177.50
-133.97
-171.80
-630.21
-117.04
growth rate -100.0% 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
EPS -0.16
0.29
0.00
1.73
-0.48
-0.95
-1.28
-0.92
-1.07
-3.81
-0.67
growth rate 100.0% -100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gross Profit 103.22
244.00
258.70
306.00
357.34
408.89
460.09
165.47
103.08
245.33
461.11
growth rate 136.4% 6.0% 18.3% 16.8% 14.4% 12.5% -64.0% -37.7% 138.0% 88.0%
R&D 93.30
115.10
147.30
214.37
302.22
354.78
461.54
634.81
661.91
610.75
growth rate 23.4% 28.0% 45.5% 41.0% 17.4% 30.1% 37.5% 4.3% -7.7%

Quarterly Statements

Item Name Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Earnings BIT -17.53
-54.19
-38.74
-42.56
-4.74
growth rate 0.0% 0.0% 0.0% 0.0%
Balance Sheet Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Acct.Receivable 251.89
261.37
318.39
363.57
384.34
growth rate 3.8% 21.8% 14.2% 5.7%
Acct.Payable 157.02
166.62
172.19
166.42
177.40
growth rate 6.1% 3.4% -3.4% 6.6%
Cur.Assets 2,050.03
2,207.14
2,241.11
2,280.07
2,407.85
growth rate 7.7% 1.5% 1.7% 5.6%
Total Assets 4,580.70
4,633.13
4,596.72
4,624.68
4,695.25
growth rate 1.1% -0.8% 0.6% 1.5%
Cash 431.40
598.03
473.98
427.41
882.18
growth rate 38.6% -20.7% -9.8% 106.4%
Inventory 457.39
475.78
468.16
473.36
508.48
growth rate 4.0% -1.6% 1.1% 7.4%
Cur.Liabilities 417.53
816.52
773.47
804.95
838.66
growth rate 95.6% -5.3% 4.1% 4.2%
Liabilities 1,767.14
1,824.46
1,789.71
1,739.58
1,780.31
growth rate 3.2% -1.9% -2.8% 2.3%
LT Debt 1,166.04
813.52
817.67
821.87
826.12
growth rate -30.2% 0.5% 0.5% 0.5%
Equity 2,813.56
2,808.66
2,807.00
2,885.10
2,914.95
growth rate -0.2% -0.1% 2.8% 1.0%
Common Shares 0.18
0.18
0.18
0.18
0.18
growth rate 0.0% 0.6% 0.6% 0.0%
Cash Flow Statement Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Capital Expenditures 42.48
39.89
30.16
22.52
49.86
growth rate -6.1% -24.4% -25.4% 121.4%
Cash Dividends
growth rate
Cash From OA 38.29
14.61
-42.51
-33.86
47.20
growth rate -61.8% -100.0% 0.0% 100.0%
Sale Purchase of Stock 5.46
14.74
13.13
31.79
growth rate 170.0% -10.9% 142.1%
FCF -4.19
-25.28
-72.67
-56.38
-2.66
growth rate 0.0% 0.0% 0.0% 0.0%
Income Statement Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Sales 334.15
358.31
373.45
372.85
391.71
growth rate 7.2% 4.2% -0.2% 5.1%
Op.Income -17.53
-54.19
-38.74
-42.56
-4.74
growth rate 0.0% 0.0% 0.0% 0.0%
IBT -20.62
54.60
-50.80
-29.18
-19.41
growth rate 100.0% -100.0% 0.0% 0.0%
Net Income -12.53
-51.39
-44.15
-16.79
-12.62
growth rate 0.0% 0.0% 0.0% 0.0%
EPS
growth rate
Gross Profit 120.57
113.70
107.17
118.24
151.41
growth rate -5.7% -5.8% 10.3% 28.0%
R&D 154.10
168.61
183.95
growth rate 9.4% 9.1%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

E (20.74)

YOY Growth Grade:

E (24.77)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE -77.42 -132.75 -2,465.50
EPS / Growth 37.1% -0.71 63.9%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 21.2%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 21.2% 40.8% 40.8%
Future PE 0.01 0.01 27.17
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.